Suppr超能文献

通过CT图像定量评估实性部分百分比以预测肺腺癌中的ROS1/ALK重排。

Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas.

作者信息

Zheng Jing, Zhou Jianya, Liu Jinpeng, Xu Jingfeng, Sun Ke, Wang Bo, Cao He, Ding Wei, Zhou Jianying

机构信息

Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.

Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.

出版信息

Oncol Lett. 2020 Sep;20(3):2987-2996. doi: 10.3892/ol.2020.11816. Epub 2020 Jul 6.

Abstract

In the present study, the predictive role of the percentage of the solid portion volume (PSV) in patients with lung adenocarcinoma was investigated. The PSV was obtained through quantitative volumetric assessments based on reconstructed CT images of lung adenocarcinoma by comparing the index among tumors with c-ros oncogene 1 (ROS1) rearrangement, epidermal growth factor receptor (EGFR) mutations, echinoderm anaplastic lymphoma kinase (ALK) rearrangements or wild-type (WT) status for the three genes. Among 1,120 patients with lung adenocarcinoma, 28 patients with ROS1 rearrangement lung adenocarcinoma, 71 with ALK rearrangement and 578 with EGFR mutations were diagnosed. PSV was quantitatively measured by semi-automated nodule assessment software and compared in patients with different mutation statuses. The PSV (presented as the median with interquartile range) in the ROS1 rearrangement group [87.9 (82.7-92.3)%] was higher than that in the EGFR mutation group [70.4 (51.4-83.4%)] and the WT group [63.0 (50.9-83.2)%; P<0.001], but was similar to that in the ALK rearrangement group [84.0 (70.3-90.0)%; P=0.251]. The area under the receiver operating characteristic curve (AUC) for the PSV to predict ROS1 or ALK rearrangement combined was 0.702 (95% CI: 0.631-0.773; P<0.001); at a cut-off value of 0.805 (when the Youden index was maximal), the predictive sensitivity was 0.697 and the specificity was 0.702. Younger age and higher PSV values were independent predictors of ROS1/ALK rearrangements. The AUC for the predictive model combined with age and PSV was 0.785. In conclusion, the PSV in the lung adenocarcinomas with ROS1 rearrangement was significantly higher compared with that in the EGFR-mutated and WT lung adenocarcinoma, but was similar to that in lung adenocarcinoma with ALK rearrangement. Younger age and higher PSV values on CT in patients with lung adenocarcinomas were predictive factors for ROS1/ALK rearrangement.

摘要

在本研究中,调查了实性部分体积百分比(PSV)在肺腺癌患者中的预测作用。通过基于肺腺癌的重建CT图像进行定量体积评估来获得PSV,方法是比较具有c-ros癌基因1(ROS1)重排、表皮生长因子受体(EGFR)突变、棘皮动物间变性淋巴瘤激酶(ALK)重排或这三个基因野生型(WT)状态的肿瘤之间的指标。在1120例肺腺癌患者中,诊断出28例ROS1重排肺腺癌患者、71例ALK重排患者和578例EGFR突变患者。通过半自动结节评估软件对PSV进行定量测量,并在不同突变状态的患者中进行比较。ROS1重排组的PSV(以中位数及四分位间距表示)为[87.9(82.7 - 92.3)%],高于EGFR突变组[70.4(51.4 - 83.4)%]和WT组[63.0(50.9 - 83.2)%;P<0.001],但与ALK重排组[84.0(70.3 - 90.0)%;P = 0.251]相似。PSV预测ROS1或ALK重排合并情况的受试者工作特征曲线(AUC)下面积为0.702(可信区间95%:0.631 - 0.773;P<0.001);在截断值为0.805(此时约登指数最大)时,预测敏感性为0.697,特异性为0.702。年龄较小和PSV值较高是ROS1/ALK重排的独立预测因素。年龄和PSV联合预测模型的AUC为0.785。总之,与EGFR突变型和WT肺腺癌相比,ROS1重排的肺腺癌中的PSV显著更高,但与ALK重排的肺腺癌相似。肺腺癌患者年龄较小且CT上PSV值较高是ROS1/ALK重排的预测因素。

相似文献

3
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.
4
Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.
Eur Radiol. 2015 May;25(5):1257-66. doi: 10.1007/s00330-014-3516-z. Epub 2015 Jan 11.
6
[Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 12;43(2):120-125. doi: 10.3760/cma.j.issn.1001-0939.2020.02.009.
7
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Lung Cancer. 2014 Mar;83(3):389-95. doi: 10.1016/j.lungcan.2014.01.003. Epub 2014 Jan 14.
8
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Lung Cancer. 2014 Feb;83(2):168-73. doi: 10.1016/j.lungcan.2013.11.019. Epub 2013 Dec 1.

本文引用的文献

1
Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Clin Lung Cancer. 2020 Mar;21(2):153-159.e3. doi: 10.1016/j.cllc.2019.10.006. Epub 2019 Oct 16.
4
Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis.
Transl Lung Cancer Res. 2015 Jun;4(3):300-9. doi: 10.3978/j.issn.2218-6751.2015.05.01.
5
Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
PLoS One. 2015 Mar 5;10(3):e0120422. doi: 10.1371/journal.pone.0120422. eCollection 2015.
6
Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.
Eur Radiol. 2015 May;25(5):1257-66. doi: 10.1007/s00330-014-3516-z. Epub 2015 Jan 11.
8
ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.
Histopathology. 2014 Aug;65(2):187-94. doi: 10.1111/his.12379. Epub 2014 Apr 3.
9
10
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验